Brief: Matinas Biopharma Announces Unanimous DSMB Approval To Progress Into Fourth And Final Cohort Of Patients In The Enact Trial Of MAT2203

Matinas BioPharma Holdings

16/12/2021 12:00

Dec 16 (Reuters) - Matinas BioPharma Holdings Inc  MTNB.A :
    * MATINAS BIOPHARMA ANNOUNCES UNANIMOUS DSMB APPROVAL TO
PROGRESS
INTO FOURTH AND FINAL COHORT OF PATIENTS IN THE ENACT TRIAL OF
MAT2203 (ORAL AMPHOTERICIN B) FOR THE TREATMENT OF CRYPTOCOCCAL
MENINGITIS
    * MATINAS BIOPHARMA HOLDINGS INC - ENROLLMENT IN FOURTH
COHORT OF
PATIENTS EXPECTED TO COMMENCE EARLY Q1 2022

Source text for Eikon:  ID:nGNX38nqjW 
Further company coverage:  MTNB.A 

 ((Reuters.Briefs@thomsonreuters.com;))